TRIB — Trinity Biotech Cashflow Statement
0.000.00%
- $1.30m
- $92.17m
- $56.83m
Annual cashflow statement for Trinity Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -28.9 | -6.39 | 0.875 | -41 | -24 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 32.3 | 28.9 | 13.8 | 39.4 | 13.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2.82 | -1.83 | -4.15 | -1.68 | -2.38 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 5.42 | 23.8 | 13.2 | -0.921 | -11.6 |
Capital Expenditures | -11.9 | -10.2 | -8.69 | -5.98 | -2.7 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | — | 0 | — | 27.5 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -11.9 | -10.2 | -8.69 | -5.98 | 24.8 |
Financing Cash Flow Items | -4 | -4 | -4.84 | -13.7 | -8.67 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -7.53 | -2.72 | -6.02 | -12.3 | -16 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -13.9 | 10.9 | -1.42 | -19.3 | -2.89 |